Arletta Pharma Solutions, a Netherlands-based biopharmaceutical company specialising in innovative therapies for women diagnosed with Female Sexual Disorders (FSD), announced on Friday the appointment of Steve van Os, MD, as chief medical officer (CMO), effective 1 June.

Dr. van Os joins Arletta as the company prepares its proposed US Phase II Monarch study of Lybrido, its lead investigational therapy for women with Female Sexual Interest/Arousal Disorder (FSIAD) and Hypoactive Sexual Desire Disorder (HSDD).

As CMO, Dr. van Os will lead Arletta's medical strategy, clinical development oversight, study execution support, safety oversight and regulatory interactions as the company advances Monarch and broader development plans for Lybrido in the United States and Europe.

Dr. van Os is a biopharmaceutical executive with more than two decades of global experience in clinical development, medical affairs and regulatory strategy across oncology, urology, women's health, endocrinology and hepatology.